Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134537 | 0.89 | RPS6KA3 (0.48) | LMNAHTTGPR55ADORA1ADORA2A | |
| SCHEMBL6133620 | 0.89 | ADORA1 (0.52) | LMNAHTTADORA1ADORA2AADORA2B | |
| SCHEMBL6133471 | 0.88 | ADORA1 (0.50) | ADORA1ADORA2AADORA2BKMT2A | |
| SCHEMBL6134043 | 0.87 | ADORA1 (0.53) | ADORA1ADORA2AADORA2BKMT2AHRH3 | |
| SCHEMBL6133989 | 0.86 | KMT2A (0.62) | LMNAHTTADORA1ADORA2AADORA2B | |
| SCHEMBL6134037 | 0.85 | RPS6KA3 (0.45) | ADORA1ADORA2AADORA2BKMT2AHRH3 | |
| SCHEMBL6134188 | 0.85 | LMNA (0.45) | LMNAHTTGPR55ADORA1ADORA2A | |
| SCHEMBL6133650 | 0.83 | ALDH1A1 (0.51) | LMNAKMT2AKDM4EMEN1POLB | |
| SCHEMBL6133617 | 0.81 | ADORA2A (0.43) | ADORA1ADORA2AADORA2BKMT2A | |
| SCHEMBL6134665 | 0.81 | ADORA1 (0.39) | ADORA1ADORA2AADORA2BKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | LMNA 3549/4885HTT 184/4885GPR55 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.